Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22667104 | 0.79 | APAF1 (0.41) | MAPTGAAAPAF1HTTALDH1A1 | |
| SCHEMBL22151601 | 0.79 | ADORA2A (0.42) | MAPTGAAAPAF1ADORA2AADORA2B | |
| SCHEMBL23400861 | 0.76 | ADORA2A (0.41) | APAF1ADORA2AADORA2BLMNA | |
| SCHEMBL13177328 | 0.74 | APAF1 (0.50) | MAPTGAAAPAF1ADORA2AADORA2B | |
| SCHEMBL11922643 | 0.72 | HTT (0.42) | MAPTAPAF1ADORA2AADORA2BHTT | |
| SCHEMBL22125784 | 0.72 | APAF1 (0.33) | APAF1 | |
| SCHEMBL13990821 | 0.71 | MAPT (0.45) | MAPTGAAAPAF1ADORA2AADORA2B | |
| SCHEMBL13683169 | 0.71 | IKBKB (0.46) | MAPTGAAAPAF1ADORA2AADORA2B | |
| SCHEMBL18159974 | 0.68 | ADORA2A (0.32) | MAPTADORA2AADORA2BNPSR1 | |
| SCHEMBL23399265 | 0.68 | ADORA2A (0.32) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | MAPT 1056/4885GAA 2781/4885APAF1 4655/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | MAPT 1930/4885GAA 2658/4885APAF1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.